There are 2789 resources available
446P - Bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (mCRC): An observational cohort study
Presenter: Alessio Amatu
Session: ePoster Display
475P - A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)
Presenter: Jordan Berlin
Session: ePoster Display
476P - Open-label phase I/II study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)
Presenter: Talia Shentzer Kutiel
Session: ePoster Display
477P - Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Heinz Josef Lenz
Session: ePoster Display
478P - TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
Presenter: Cristina Santos
Session: ePoster Display
479P - Difference gene mutations among CRC patients with MSS and MSI-H types in China
Presenter: Jianjun Yang
Session: ePoster Display
480P - Gene expression of NANOG and NANOGP8 in colorectal cancer
Presenter: Hiroyuki Arai
Session: ePoster Display
481P - Evaluation of serum mid-infrared spectroscopy as new prognostic marker for bevacizumab-based chemotherapy in first-line treatment of metastatic colorectal cancer
Presenter: Romain Chautard
Session: ePoster Display
483P - The correlation analysis between MUC16 mutation and immunotherapy predictive biomarkers in colon adenocarcinoma
Presenter: Gong Chen
Session: ePoster Display
484P - CD300c blockade promotes anti-cancer immunity and synergizes with immune checkpoint inhibitor in colon cancer
Presenter: HyeRim Shin
Session: ePoster Display